Heartflow (NASDAQ:HTFL) Upgraded at Wall Street Zen

Heartflow (NASDAQ:HTFL - Get Free Report) was upgraded by stock analysts at Wall Street Zen from a "hold" rating to a "buy" rating in a report issued on Sunday, Wall Street Zen reports.

Several other equities research analysts have also issued reports on HTFL. Piper Sandler reiterated an "overweight" rating and set a $64.00 target price (up from $45.00) on shares of Heartflow in a research report on Tuesday, October 20th. UBS Group initiated coverage on shares of Heartflow in a research note on Wednesday, September 9th. They issued a "neutral" rating and a $55.00 price target for the company. Wells Fargo & Company increased their price target on shares of Heartflow from $39.00 to $70.00 and gave the stock an "overweight" rating in a report on Friday. Morgan Stanley raised their price objective on shares of Heartflow from $35.00 to $40.00 and gave the company an "equal weight" rating in a research report on Friday, August 14th. Finally, JPMorgan Chase & Co. lifted their price objective on shares of Heartflow from $35.00 to $45.00 and gave the stock an "overweight" rating in a report on Friday, August 14th. One analyst has rated the stock with a Strong Buy rating, eight have given a Buy rating, two have issued a Hold rating and one has issued a Sell rating to the stock. According to MarketBeat.com, the company has a consensus rating of "Moderate Buy" and a consensus target price of $60.12.

Heartflow Price Performance

Shares of NASDAQ:HTFL traded down $11.46 on Friday, hitting $48.46. The company's stock had a trading volume of 3,705,135 shares, compared to its average volume of 1,763,967. The company has a market capitalization of $4.21 billion, a PE ratio of -52.67 and a beta of 2.50. The company has a 50-day simple moving average of $51.91 and a 200 day simple moving average of $35.23. Heartflow has a 1 year low of $20.13 and a 1 year high of $60.65.

Heartflow (NASDAQ:HTFL - Get Free Report) last issued its quarterly earnings data on Thursday, November 12th. The company reported ($0.03) EPS for the quarter, topping the consensus estimate of ($0.18) by $0.15. Heartflow had a negative return on equity of 20.42% and a negative net margin of 33.11%. The company had revenue of $72.86 million during the quarter. During the same period in the previous year, the firm posted ($0.27) EPS. On average, equities research analysts expect that Heartflow will post -0.75 earnings per share for the current fiscal year.

Insider Activity at Heartflow

In related news, CFO Vikram Verghese sold 29,714 shares of the business's stock in a transaction that occurred on Friday, September 11th. The stock was sold at an average price of $50.06, for a total value of $1,487,482.84. Following the completion of the sale, the chief financial officer owned 184,789 shares in the company, valued at $9,250,537.34. The trade was a 13.85% decrease in their position. The transaction was disclosed in a filing with the SEC, which is available through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO John Farquhar sold 38,900 shares of the business's stock in a transaction that occurred on Monday, October 12th. The stock was sold at an average price of $49.57, for a total value of $1,928,273.00. Following the completion of the sale, the chief executive officer owned 283,014 shares of the company's stock, valued at $14,029,003.98. The trade was a 12.08% decrease in their position. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. In the last three months, insiders have sold 332,403 shares of company stock valued at $16,602,786. Corporate insiders own 7.70% of the company's stock.

Institutional Investors Weigh In On Heartflow

Hedge funds have recently made changes to their positions in the business. GAMMA Investing LLC grew its holdings in shares of Heartflow by 75.1% during the 3rd quarter. GAMMA Investing LLC now owns 641 shares of the company's stock valued at $32,000 after purchasing an additional 275 shares during the last quarter. IFP Advisors Inc raised its position in Heartflow by 844.7% in the 3rd quarter. IFP Advisors Inc now owns 803 shares of the company's stock worth $40,000 after purchasing an additional 718 shares during the period. Integrated Wealth Concepts LLC bought a new stake in Heartflow in the second quarter worth $53,000. Essential Partners LLC bought a new stake in Heartflow in the first quarter worth $57,000. Finally, Allworth Financial LP boosted its position in Heartflow by 116.4% during the third quarter. Allworth Financial LP now owns 1,145 shares of the company's stock valued at $57,000 after buying an additional 616 shares during the period.

Key Heartflow News

These are some of the HTFL news items that stood out recently:

• Positive Sentiment: Heartflow raised its 2026 revenue guidance to $262 million–$264 million, above the approximately $248.5 million consensus, signaling stronger expected growth. Financial results and guidance
• Positive Sentiment: Wells Fargo, Canaccord Genuity, Stifel and Baird raised their price targets to $68–$70 and maintained positive ratings, reflecting improved analyst expectations. Wells Fargo rating Canaccord Genuity rating Stifel rating Baird rating
• Negative Sentiment: A report said Heartflow’s CEO sold about $2.17 million worth of stock. Insider selling can concern investors, though the report alone does not establish the reason for the sale. CEO stock sale

Heartflow Company Profile

HeartFlow, Inc. is a medical technology company that develops noninvasive tools to help clinicians assess coronary artery disease. Its platform analyzes coronary CT angiography scans to create personalized models of a patient's coronary arteries and provide information that can support diagnosis and treatment planning. The company's offerings include HeartFlow FFR CT Analysis, which estimates blood flow and the effects of artery narrowing, and tools for assessing coronary plaque. The technology combines medical imaging with computational analysis and artificial intelligence, giving clinicians information without requiring an invasive procedure to measure blood flow.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.